

# Full Public Health Value Propositions (FPHVP) for Vaccines

Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, Geneva, 17-18 April 2018



World Health  
Organization

# What are FPHVPs and why is IVB interested?

- IVB's remit includes facilitating development of new and improved vaccines against priority pathogens, and supporting countries with introduction of these vaccines.
- Dual [i.e, high-income country (HIC) and low- and middle-income country (LMIC)] market vaccines in development against priority pathogens:
  - Often target HIC markets, initially.
  - Require additional resources to concomitantly develop and introduce vaccines suitable for LMIC uptake.
- Sustained investment and commitment to development of vaccines that are suitable for use in LMIC contexts are needed early in product development planning, to provide evidence that enables efficient and effective policy decision-making.
- The FPHVP for vaccines is *a concept in development*, that describes the global value of a vaccine, including from an LMIC perspective. It aims to articulate the full direct (individual) and indirect (population) effects of a vaccine.
- For IVB, FPHVPs support decision-making across the continuum of vaccine development and uptake with a line-of-sight to sustainable public health impact



# Overview of the FPHVP session

- Concept and status of FPHVP:
  - David Kaslow, Chair of Product Development for Vaccines Advisory Committee (PDVAC)
- Global economic investment case for vaccines:
  - Mark Jit, Member of Immunization and vaccines related implementation research advisory committee (IVIR-AC)
- Discussion



# Questions for consideration

Given that FPHVPs are meant to support decision-making across the continuum of vaccine development and uptake with a line-of-sight to sustainable public health impact:

- Would a common framework be helpful to capture the FPHVP of a vaccine?
- How could FPHVPs help to inform stakeholders and decision-making?
  - What type of decisions would it help to inform: investment, prioritization (selection and de-selection), policy recommendations, others?
- What information/types of analyses would be helpful to capture in FPHVPs at various product development stages, e.g., in early vs late stage development?
  - **Early stage FPHVP (PDVAC):** What components of early stage FPHVPs does SAGE suggest be prioritized?
  - **Late stage FPHVP (SAGE):** If and how would SAGE use FPHVPs in pre-licensure, pre-policy, and post-policy discussions and recommendations?
- If development of FPHVPs for vaccines is considered useful, how can they be resourced?